Niox Group PLC Directorate Change

RNS Number : 4626U

Niox Group PLC

01 July 2024

 

 

 

NIOX GROUP PLC

("NIOX" or the "Company" and, together with its subsidiaries, the "Group")

 

Directorate Change

 

 

Oxford, UK - 1 July 2024: NIOX Group plc (AIM: NIOX), a medical device company focused on point of care asthma diagnosis and management, is pleased to announce the appointment of Robert Naylor as Non-Executive Director and Chair of the Audit and Risk Committee, with immediate effect.

 

Robert has over 25 years' experience in capital markets specialising in healthcare and investment companies and is currently Chief Executive Officer of Intuitive Investments Group plc, an investment company which is quoted on the Specialist Fund Segment of the London Stock Exchange's Main Market, providing investors with exposure to a portfolio of fast-growing technology and life sciences businesses. Additionally, Robert is Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc.

 

Previously, Robert was Non-Executive Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. He has also served as a Non-Executive Director of Light Science Technologies Holdings plc, an AIM-quoted controlled environment agriculture company. Earlier in his career Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996.

 

 

Ian Johnson, NIOX's Executive Chairman, said: "I am delighted to welcome Robert to the NIOX Board and look forward to working with him as we continue to build on our global leadership. Robert brings extensive business and corporate development experience to assist the executive team in implementing its growth strategy."

 

 

Additional information in respect of the AIM Rules

 

The following information regarding the appointment of Robert Graham Naylor (aged 49) is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies ("AIM Rules"):

 

Current directorships/partnerships	Past directorships/partnerships
·      Intuitive Investments Group Plc ·      IIG Assets Ltd ·      Hipgnosis SFH XX Limited ·      Hipgnosis SFH XIII Limited ·      Hipgnosis SFH XIX Limited ·      Hipgnosis SFH I Limited ·      Hipgnosis Holdings UK Limited ·      Rubyruby (London) Limited ·      Pb Songs Ltd ·      Kennedy Publishing & Productions Limited ·      Deamon Limited	·      Round Hill Music Royalty Fund Limited ·      RHMRF2 Limited ·      RHMRF3 Limited ·      Light Science Technologies Holdings plc ·      Concord Copyrights No.1 Limited (formerly RHMRF1 Limited)

 

As at the date of this announcement, Robert Naylor holds no interest in the Company.

 

Save as set out above, there is no further information to be disclosed in respect of Robert Naylor under Schedule 2(g) of the AIM Rules for Companies.

 

Contacts:
NIOX Group plc Ian Johnson, Executive Chairman Michael Roller, Chief Financial Officer	[phone]
Singer Capital Markets (Nominated Adviser and Joint Broker) Aubrey Powell / Jen Boorer / James Todd	[phone]
Investec Bank plc (Financial Adviser and Joint Broker) Edward Knight / Bruce Garrow / Lydia Zychowska	[phone]

 

 

About NIOX

Our mission is to improve asthma diagnosis and management by greater patient access to FeNO testing. Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or are misdiagnosed. The Group is engaged in the design, development, and commercialisation of medical devices for the measurement of FeNO, a precise biomarker for asthma. Our market leading device, NIOX VERO®, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical research organisations for respiratory studies.

 

NIOX provides products and services via its direct sales organisation and extensive distributor network in 50 countries. For more information, please visit www.niox.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BOAQKFBBOBKDQAB